Which groups of people who are contraindicated by Nirapali and Abiraterone Tablets need special attention?

Niraparib Abiraterone Tablets (Akeega) is a new oral compound preparation for targeted treatment of prostate cancer that has been approved in many places around the world, but during clinical use, not all patients are suitable for taking it. Its banned population is closely related to the pharmacokinetic properties, metabolism mode, and potential safety risks of the drug ingredients. Before prescribing, doctors need to pay special attention to the exclusion criteria for certain high-risk groups based on individual differences.

First of all, Akeega is specifically contraindicated in patients with severe hepatic insufficiency.Akeega is specifically contraindicated. Since its active ingredient abiraterone is mainly metabolized by the liver, it may cause drug accumulation in a state of impaired liver function, exacerbating the risk of hepatotoxicity. At the same time, abiraterone can inhibit CYP17 enzyme activity, interfere with the steroid synthesis process, and aggravate adrenocortical dysfunction, so such patients are more likely to suffer from electrolyte disorders, abnormal heart rhythm and other adverse reactions.

Secondly, female patients, especially pregnant and lactating women, are strictly excluded from the scope of application. Akeega is not a drug for women. Its PARP inhibitor component niraparib showed embryotoxicity in animal experiments and may have irreversible effects on the fetus. Therefore, women of childbearing age should strictly avoid exposure to this drug. Even during drug preparation or care, exposure protection is required.

In addition, for male patients with severe cardiovascular disease, recent history of myocardial infarction or arrhythmia, the risk also needs to be carefully assessed. Abiraterone may cause hypertension, water and sodium retention and other reactions. If it is not used together with hormonal drugs such as prednisone, the risk will be further increased. Therefore this drug is generally not recommended for patients with uncontrolled high blood pressure or heart failure.

Finally,The efficacy of Akeega in patients with BRCA mutation-negative prostate cancer is not clear, and its use should be avoided in non-indicated groups. Because its core mechanism relies on targeted killing of cells with DNA repair defects, if the patient does not have relevant genetic defects, it may result in limited benefits and increased side effects.

Reference materials:https://www.drugs.com/akeega.html